Antimicrobial susceptibility of Clostridium difficile isolated in Thailand

Antibiotics Smart Use: a workable model for promoting the rational use of medicines in Thailand

(2016) Nithima Sumpradit et al.   BULLETIN OF THE WORLD HEALTH ORGANIZATION

Pan-European longitudinal surveillance of antibiotic resistance among prevalent Clostridium difficile ribotypes

(2015) J. Freeman et al.   CLINICAL MICROBIOLOGY AND INFECTION

Diversity and Evolution in the Genome of Clostridium difficile

(2015) Daniel R. Knight et al.   CLINICAL MICROBIOLOGY REVIEWS

Economic assessment of fidaxomicin for the treatment of Clostridium difficile infection (CDI) in special populations (patients with cancer, concomitant antibiotic treatment or renal impairment) in Spain

(2015) C. Rubio-Terrés et al.   EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES

Administration of Spores of NontoxigenicClostridium difficileStrain M3 for Prevention of RecurrentC difficileInfection

(2015) Dale N. Gerding et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Surveillance for antimicrobial resistance in Australian isolates ofClostridium difficile, 2013–14

(2015) Daniel R. Knight et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Correction: Molecular Epidemiology of Clostridium difficile Infection in a Large Teaching Hospital in Thailand

(2015) Popchai Ngamskulrungroj et al.   PLoS One

Strain Types and Antimicrobial Resistance Patterns of Clostridium difficile Isolates from the United States, 2011 to 2013

(2014) Isabella A. Tickler et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Phage  C2 Mediates Transduction of Tn6215, Encoding Erythromycin Resistance, between Clostridium difficile Strains

(2013) S. Goh et al.   mBio

Horizontal gene transfer converts non-toxigenic Clostridium difficile strains into toxin producers

(2013) Michael S.M. Brouwer et al.   Nature Communications

Characterizations of Clinical Isolates of Clostridium difficile by Toxin Genotypes and by Susceptibility to 12 Antimicrobial Agents, Including Fidaxomicin (OPT-80) and Rifaximin: a Multicenter Study in Taiwan

(2012) Chun-Hsing Liao et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Analysis of a Clostridium difficile PCR ribotype 078 100 kilobase island reveals the presence of a novel transposon, Tn6164

(2012) Jeroen Corver et al.   BMC MICROBIOLOGY

Epidemiology of Clostridium difficile infections in a tertiary-care hospital in Korea

(2012) J. Kim et al.   CLINICAL MICROBIOLOGY AND INFECTION

Association between PCR ribotypes and antimicrobial susceptibility among Clostridium difficile isolates from healthcare-associated infections in South Korea

(2012) Jieun Kim et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Comparative Susceptibilities to Fidaxomicin (OPT-80) of Isolates Collected at Baseline, Recurrence, and Failure from Patients in Two Phase III Trials of Fidaxomicin against Clostridium difficile Infection

(2011) Ellie J. C. Goldstein et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Rifampin and Rifaximin Resistance in Clinical Isolates of Clostridium difficile

(2008) J. R. O'Connor et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY